Profile

Katherine G. Tarlock, MD

Katherine G. Tarlock, MD

Hematology-Oncology

On staff since September 2014

Academic Title: Acting Instructor

Research Center: Center for Clinical and Translational Research

"The privilege of caring for patients and families during challenging medical diagnoses is what drew me to this field and continues to be the best part of my job. I am dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care."

  • Award Name Award Description Awarded By Award Date
    Alpha Omega Alpha Medical Honor Society
    Pediatric Clerkship Award Chicago Medical School
    Outstanding Pediatric Resident Award Lucile Packard Children's Hospital
    Alberta Corkery Fellowship Travel Award
    American Society of Hematology Abstract Achievement Award
    Outstanding Presentation Award Seattle Children's Hospital Fellow Research Day
    • Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S
      Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
      26644412 Clinical cancer research : an official journal of the American Association for Cancer Research , 2016 Apr, 15 - 2016 Apr, 15 : 22(8)1951-7 PMCID: PMC4834220
    • Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S
      Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
      26644412 Clinical cancer research : an official journal of the American Association for Cancer Research , 2015 Dec. 7 - 2015 Dec. 7
    • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
      Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
      25662999 Pediatric blood and cancer , 2015 June - 2015 June : 62(6)1048-54
  • Grant Title Grantor Amount Award Date
    Targeting Novel Pediatric-Specific FLT3 Mutations Alexs Lemonade Stand Foundation Feb. 1, 2016 - Jan. 31, 2018
    Validation of Mesothelin as a Therapeutic Target in Childhood AML Childrens Oncology Group, Integrated Translational Science Center, Hematology Jan. 1, 2016 - June 1, 2016
    Novel Therapeutic Strategy Identification in Relapsed FLT3/ITD Acute Myeloid Leukemia Hyundai Hope on Wheels, Young Investigator Award Dec. 31, 2015 - Dec. 31, 2017
    Pathway Directed Treatment for Refractory AML Sts Baldricks Foundation, St's Baldrick's Consortium Grant July 1, 2015 - June 30, 2016
    Identification of Resistance Mechanisms and Novel Therapeutic Strategies in Tyrosine Kinase Inhibitor Resistant FLT3/ITD Acute Myeloid Leukemia Alexs Lemonade Stand Foundation, ALSF Young Investigator Award July 1, 2014 - June 30, 2016
    Biology and Prognostic Implications of FLT3 Mutations in AML National Cancer Institute/National Institutes of Health, R01 CA 114563, Sept. 20, 2012 - July 31, 2017

Overview

Board Certification(s)

Pediatrics

Medical/Professional School

Rosalind Franklin University of Medicine and Science - Chicago Medical School, North Chicago

Residency

Pediatrics, Stanford University Lucile Packard Children's Hospital, Palo Alto

Fellowship

Pediatric Hematology-Oncology, Seattle Children's Hospital, Seattle

Clinical Interests

Leukemias, adolescents and young adults

Research Description

Acute myeloid leukemia, chemotherapy resistance, identification of novel therapeutic agents in childhood leukemias